Amjevita was given the thumbs up by the Food and Drug Administration (FDA) in September, meaning Amgen could be the first to take a share of Humira’s $8.4bn US revenues once launched.
But Amgen is far from alone with its adalimumab biosimilar, as a report from PNS Pharma claims there are at least 33 versions in the clinical pipeline.
“More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years,” the report says.
So who are the companies looking to take on AbbVie? Well Biopharma-Reporter has laid them all out for you to find in our ‘Humira Biosimilar Word Search.’